United Kingdom · Question · Written question
UIN 47379
Tixagevimab/cilgavimab
Introduced
5 September 2022
Last action
20 September 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 September 2022
Summary
To ask the Secretary of State for Health and Social Care, when he expects NICE's review of Evusheld to be concluded.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
5 September 2022
Written question
To ask the Secretary of State for Health and Social Care, when he expects NICE's review of Evusheld to be concluded.
Source: Commons
20 September 2022
Answer
On 10 August 2022, the Department referred tixagevimab and cilgavimab (Evusheld) to the National Institute for Health and Care Excellence (NICE) to evaluate its clinical and cost effectiveness for preventing COVID-19. Between 29 July and 12 August, NICE c...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-09-05/47379
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1505163
- uk · wq-1505163 · source updated 20 September 2022